Form 10-Q Revance Therapeutics, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Revance Therapeutic (RVNC) PT Lowered to $31 at Stifel
November 10, 2021 6:49 AM ESTStifel analyst Annabel Samimy lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $31.00 (from $33.00) while maintaining a Buy rating.
The analyst commented, "RVNC reported solid revenues ($19.8mn/ Cons $20.3) from steady RHA-filler sales ($18.3mn) in a seasonally difficult quarter and meaningful expansion of... More
